relapses

Most disability worsening on Ocrevus not tied to relapses: Study

Among multiple sclerosis (MS) patients treated with Ocrevus (ocrelizumab), most of the disability worsening they experience is not associated with any relapse activity, according to an analysis of real-world data. “We present real-world data from our multiple sclerosis center underlining that in a typical population of relapsing MS…

Analysis Finds Acthar Gel Cost-effective for MS Relapses

Acthar Gel (repository corticotropin injection) was found to be a cost-effective treatment for people with multiple sclerosis (MS) experiencing a relapse, according to an economic analysis. Notably, the economic value of Acthar Gel was greater than that of alternative treatments ā€”Ā plasmapheresis and intravenous immunoglobulin ā€” from the…

Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations

Ocrevus (ocrelizumab) reduces relapse risk and slows disability progression inĀ multiple sclerosis (MS) but also is associated with higher hospitalization rates in older people with relapsing forms of the disease, a new observational study reports. Hospitalizations ā€” which occurred mainly due to urinary tract infections ā€” were more frequent…

Anxiety and Depression Linked to RRMS Relapse Risk, Study Finds

Comorbidities such as anxiety and depression are associated with a significantly increased risk of relapse in people with relapsing-remitting multiple sclerosis (RRMS), a clinical trial analysis has found.Ā  Anxiety and abnormal blood lipids (fats) also increased the risk of any RRMS disease activity.Ā  Based on those findings, researchers…

Study of Stem Cell Therapy for Highly Active RRMS Honored by CR Forum

The MISTĀ Phase 2 clinical trial, supporting the potential of hematopoietic (blood cell-producing)Ā stem cell transplant (HSCT) to significantly slow disability progression in highly activeĀ relapsing-remitting multiple sclerosis (RRMS)Ā patients, has received a Distinguished Clinical Research Achievement Award from the Clinical Research (CR) Forum. Five years after the transplant, most…